Plan B Boosts Barr Branded Sales; Firm Teams With Teva On Generic Allegra
This article was originally published in The Tan Sheet
Barr Labs expects an increase in Plan B prescription sales to contribute to the firm's growing revenues for its proprietary product portfolio
You may also be interested in...
FDA believes additional information on whether a drug can be marketed both Rx and OTC for the same indication is needed before a decision can be reached on Barr Labs' switch application for Plan B
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Combe sells most of its OTC brands